Institutional Conflict of Interest: Immatics US Inc

MD Anderson and Immatics US Inc (Immatics) are parties to a Collaboration and License Agreement involving licensed subject matter ("Licensed Subject Matter") licensed to Immatics and the related collaborative research to be conducted at MD Anderson and Immatics US Inc.

Under the agreement, MD Anderson has a right to license fees in the form of cash payments and/or shares of common stock, running royalties on net sales of licensed products, milestone payments in the form of cash and/or shares of common stock, patent prosecution expenses, annual maintenance fees, a portion of sublicensing consideration and termination fees. Because of MD Anderson's financial interest in the success of Licensed Subject Matter, MD Anderson has a conflict of interest in regards to its conduct of the research conducted using the Licensed Subject Matter.

Because MD Anderson is committed to the integrity of research, the protection of human subjects and the effective management of its financial conflict of interest in relation to its research activities, MD Anderson has implemented an Institutional Conflict of Interest Management and Monitoring Plan (Plan) to manage and monitor the conflict of interest with respect to MD Anderson's conduct of the research involving the Licensed Subject Matter. The Plan has been approved by the President of MD Anderson and the Executive Vice Chancellor for Health Affairs for The University of Texas System (EVC) and has been implemented by MD Anderson.

The Plan requirements include:

- Oversight of MD Anderson's clinical trials by an external, independent Institutional Review Board (IRB).
- Conduct of phase III studies, or phase II studies aimed at gaining FDA approval, as multi-institutional trials with the lead principal investigator being from an institution other than MD Anderson.
- Review of safety and efficacy data by an external, independent Data Safety Monitoring Board (DSMB).
- Monitoring of manufacturing and testing activities by MD Anderson's Investigational New Drug Office and reported to the IRB.
- Oversight of MD Anderson's IND-enabling preclinical studies by an external contract research organization (External CRO).
- Periodic reporting to the EVC or to the Institutional Conflict of Interest Committee (ICOIC) that MD Anderson is organizing.
- Disclosure of the MD Anderson financial interest to all clinical trial patients, to all members of the related clinical trials research teams, and in all publications and oral presentations concerning the clinical trials.
- Posting of this summary on MD Anderson's public website.
- Engagement of a non-MD Anderson ethicist to address any questions or concerns that Immatics US Inc clinical trial participants' may have pertaining to the MD Anderson financial interest and conflict of interest.
- Referral of any concerns/complaints related to MD Anderson's compliance with the Plan, or its financial conflict of interest, to the Office of General Counsel for The University of Texas System.
- Annual review of MD Anderson's compliance with the Plan by The University of Texas Systemwide Compliance Officer, with a written report of the review to be provided to the EVC.
- Prohibition against any MD Anderson institutional decision maker with a financial relationship with Immatics US Inc being involved in any negotiations with Immatics US Inc or its known affiliates.

MD Anderson will modify the Plan, if and when necessary, to address any subsequent matters implicating the integrity of the Clinical Trials and to comply with any additional requirements deemed necessary by the EVC to ensure the integrity of the Clinical Trials.

Last updated 4/3/2017